{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:42:13Z","timestamp":1792978933735,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009326","name":"The Cancer Research Society","doi-asserted-by":"crossref","award":["944456"],"award-info":[{"award-number":["944456"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009326","name":"The Cancer Research Society","doi-asserted-by":"crossref","award":["944456"],"award-info":[{"award-number":["944456"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15650-x","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:26:15Z","timestamp":1769840775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Senogenic-senolytic treatment strategies enhance tumor control and can improve survival in murine cancer models: a systematic review"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0544-7102","authenticated-orcid":false,"given":"Eleane C.B.","family":"Hamburger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-3787","authenticated-orcid":false,"given":"Paolo","family":"Brigato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-8177","authenticated-orcid":false,"given":"Derek H.","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1288-2149","authenticated-orcid":false,"given":"Lisbet","family":"Haglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"7","key":"15650_CR1","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/s12276-025-01480-7","volume":"57","author":"A Ajoolabady","year":"2025","unstructured":"Ajoolabady A, et al. Hallmarks of cellular senescence: biology, mechanisms, regulations. Exp Mol Med. 2025;57(7):1482\u201391.","journal-title":"Exp Mol Med"},{"issue":"1","key":"15650_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41368-025-00380-w","volume":"17","author":"J Luo","year":"2025","unstructured":"Luo J, et al. Persistent accumulation of therapy-induced senescent cells: an obstacle to long-term cancer treatment efficacy. Int J Oral Sci. 2025;17(1):59.","journal-title":"Int J Oral Sci"},{"key":"15650_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030484","author":"MP Mongiardi","year":"2021","unstructured":"Mongiardi MP, et al. Cancer response to therapy-induced senescence: a matter of dose and timing. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13030484.","journal-title":"Cancers (Basel)"},{"key":"15650_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114765","volume":"193","author":"V Carpenter","year":"2021","unstructured":"Carpenter V, et al. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy. Biochem Pharmacol. 2021;193:114765.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"15650_CR5","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1038\/s41467-019-10460-1","volume":"10","author":"H Fleury","year":"2019","unstructured":"Fleury H, et al. Exploiting interconnected synthetic lethal interactions between PARP Inhibition and cancer cell reversible senescence. Nat Commun. 2019;10(1):2556.","journal-title":"Nat Commun"},{"issue":"42","key":"15650_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202507248","volume":"12","author":"L Yu","year":"2025","unstructured":"Yu L, et al. Senescence-inducing therapy sequential NIR-II mild photothermal\/senolytic therapy of triple negative breast cancer. Adv Sci. 2025;12(42):e07248.","journal-title":"Adv Sci"},{"key":"15650_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"JP Copp\u00e9","year":"2010","unstructured":"Copp\u00e9 JP, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99\u2013118.","journal-title":"Annu Rev Pathol"},{"key":"15650_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biom15060860","author":"T Saliev","year":"2025","unstructured":"Saliev T, Singh PB. Targeting senescence: a review of senolytics and senomorphics in anti-aging interventions. Biomolecules. 2025. https:\/\/doi.org\/10.3390\/biom15060860.","journal-title":"Biomolecules"},{"key":"15650_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030386","author":"J Lafontaine","year":"2021","unstructured":"Lafontaine J, et al. Senolytic targeting of Bcl-2 anti-apoptotic family increases cell death in irradiated sarcoma cells. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13030386.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"15650_CR10","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1002\/med.21702","volume":"40","author":"J Martel","year":"2020","unstructured":"Martel J, et al. Emerging use of senolytics and senomorphics against aging and chronic diseases. Med Res Rev. 2020;40(6):2114\u201331.","journal-title":"Med Res Rev"},{"key":"15650_CR11","doi-asserted-by":"publisher","first-page":"1189015","DOI":"10.3389\/fonc.2023.1189015","volume":"13","author":"S Xiao","year":"2023","unstructured":"Xiao S, et al. Cellular senescence: a double-edged sword in cancer therapy. Front Oncol. 2023;13:1189015.","journal-title":"Front Oncol"},{"issue":"3","key":"15650_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1074\/jbc.RA118.004712","volume":"294","author":"SS Gayle","year":"2019","unstructured":"Gayle SS, et al. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells. J Biol Chem. 2019;294(3):875\u201386.","journal-title":"J Biol Chem"},{"key":"15650_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1605085","volume":"15","author":"C Chen","year":"2025","unstructured":"Chen C, et al. Senescence-associated secretory phenotype in lung cancer: remodeling the tumor microenvironment for metastasis and immune suppression. Front Oncol. 2025;15:1605085.","journal-title":"Front Oncol"},{"issue":"1","key":"15650_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02096-7","volume":"23","author":"Z Dong","year":"2024","unstructured":"Dong Z, et al. Cellular senescence and SASP in tumor progression and therapeutic opportunities. Mol Cancer. 2024;23(1):181.","journal-title":"Mol Cancer"},{"key":"15650_CR15","doi-asserted-by":"publisher","first-page":"116474","DOI":"10.1016\/j.biopha.2024.116474","volume":"174","author":"L Wang","year":"2024","unstructured":"Wang L, et al. Senolytic drugs dasatinib and Quercetin combined with carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer. Biomed Pharmacother. 2024;174:116474.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"15650_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1124\/molpharm.121.000354","volume":"101","author":"F Ahmadinejad","year":"2022","unstructured":"Ahmadinejad F, et al. Senolytic-mediated elimination of head and neck tumor cells induced into senescence by cisplatin. Mol Pharmacol. 2022;101(3):168\u201380.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"15650_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02419-2","volume":"24","author":"T Feng","year":"2025","unstructured":"Feng T, et al. Cellular senescence in cancer: from mechanism paradoxes to precision therapeutics. Mol Cancer. 2025;24(1):213.","journal-title":"Mol Cancer"},{"issue":"6","key":"15650_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022;22(6):340\u201355.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"15650_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.18632\/aging.101202","volume":"9","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-X(L) inhibitors, A1331852 and A1155463. Aging. 2017;9(3):955\u201363.","journal-title":"Aging"},{"key":"15650_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1146\/annurev-pharmtox-050120-105018","volume":"61","author":"PD Robbins","year":"2021","unstructured":"Robbins PD, et al. Senolytic drugs: reducing senescent cell viability to extend health span. Annu Rev Pharmacol Toxicol. 2021;61:779\u2013803.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"15650_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1549282","volume":"15","author":"AR Schreiber","year":"2025","unstructured":"Schreiber AR, et al. Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. Front Oncol. 2025;15:1549282.","journal-title":"Front Oncol"},{"issue":"3","key":"15650_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2017.1299666","volume":"4","author":"M Demaria","year":"2017","unstructured":"Demaria M. Senescent cells: new target for an old treatment? Mol Cell Oncol. 2017;4(3):e1299666.","journal-title":"Mol Cell Oncol"},{"key":"15650_CR23","doi-asserted-by":"publisher","first-page":"111591","DOI":"10.1016\/j.mad.2021.111591","volume":"200","author":"EO Wissler Gerdes","year":"2021","unstructured":"Wissler Gerdes EO, et al. Strategies for late phase preclinical and early clinical trials of senolytics. Mech Ageing Dev. 2021;200:111591.","journal-title":"Mech Ageing Dev"},{"issue":"9","key":"15650_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.tcb.2018.04.006","volume":"28","author":"CJ Sieben","year":"2018","unstructured":"Sieben CJ, et al. Two-step senescence-focused cancer therapies. Trends Cell Biol. 2018;28(9):723\u201337.","journal-title":"Trends Cell Biol"},{"key":"15650_CR25","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"1","key":"15650_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, et al. SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14(1):43.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"15650_CR27","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1038\/s41467-020-15719-6","volume":"11","author":"M Wakita","year":"2020","unstructured":"Wakita M, et al. A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells. Nat Commun. 2020;11(1):1935.","journal-title":"Nat Commun"},{"key":"15650_CR28","doi-asserted-by":"publisher","first-page":"110205","DOI":"10.1016\/j.intimp.2023.110205","volume":"119","author":"HJ Jia","year":"2023","unstructured":"Jia HJ, et al. Artesunate ameliorates irinotecan-induced intestinal injury by suppressing cellular senescence and significantly enhances anti-tumor activity. Int Immunopharmacol. 2023;119:110205.","journal-title":"Int Immunopharmacol"},{"key":"15650_CR29","doi-asserted-by":"publisher","first-page":"110465","DOI":"10.1016\/j.intimp.2023.110465","volume":"121","author":"J Xia","year":"2023","unstructured":"Xia J, et al. Atorvastatin calcium alleviates 5-fluorouracil-induced intestinal damage by inhibiting cellular senescence and significantly enhances its antitumor efficacy. Int Immunopharmacol. 2023;121:110465.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"15650_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12672-023-00747-7","volume":"14","author":"J Xia","year":"2023","unstructured":"Xia J, et al. Artesunate alleviates 5-fluorouracil-induced intestinal damage by suppressing cellular senescence and enhances its antitumor activity. Discover Oncol. 2023;14(1):139.","journal-title":"Discover Oncol"},{"key":"15650_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113513","volume":"143","author":"X Ren","year":"2024","unstructured":"Ren X, et al. Caulerpin alleviates cyclophosphamide-induced ovarian toxicity by modulating macrophage-associated granulosa cell senescence during breast cancer chemotherapy. Int Immunopharmacol. 2024;143:113513.","journal-title":"Int Immunopharmacol"},{"key":"15650_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jconrel.2025.01.029","volume":"379","author":"Z Guo","year":"2025","unstructured":"Guo Z, et al. Antibody functionalized curcuma-derived extracellular vesicles loaded with doxorubicin overcome therapy-induced senescence and enhance chemotherapy. J Control Release. 2025;379:377\u201389.","journal-title":"J Control Release"},{"issue":"2","key":"15650_CR33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00280-019-04025-8","volume":"85","author":"Z Wang","year":"2020","unstructured":"Wang Z, et al. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by Olaparib. Cancer Chemother Pharmacol. 2020;85(2):273\u201384.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"15650_CR34","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s42255-021-00491-8","volume":"3","author":"Q Xu","year":"2021","unstructured":"Xu Q, et al. The flavonoid Procyanidin C1 has senotherapeutic activity and increases lifespan in mice. Nat Metabolism. 2021;3(12):1706\u201326.","journal-title":"Nat Metabolism"},{"issue":"2","key":"15650_CR35","doi-asserted-by":"publisher","first-page":"pbac007","DOI":"10.1093\/pcmedi\/pbac007","volume":"5","author":"L Deng","year":"2022","unstructured":"Deng L, et al. Blockade of integrin signaling reduces chemotherapy-induced premature senescence in collagen cultured bladder cancer cells. Precis Clin Med. 2022;5(2):pbac007.","journal-title":"Precis Clin Med"},{"issue":"3","key":"15650_CR36","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.ymthe.2022.01.025","volume":"30","author":"P Chaturvedi","year":"2022","unstructured":"Chaturvedi P, et al. Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells. Mol Ther. 2022;30(3):1171\u201387.","journal-title":"Mol Ther"},{"key":"15650_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1422363","volume":"15","author":"AAA Abdelmoaty","year":"2024","unstructured":"Abdelmoaty AAA, et al. Senolytic effect of triterpenoid complex from ganoderma lucidum on adriamycin-induced senescent human hepatocellular carcinoma cells model in vitro and in vivo. Front Pharmacol. 2024;15:1422363.","journal-title":"Front Pharmacol"},{"issue":"11","key":"15650_CR38","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1111\/cas.15961","volume":"114","author":"T Wang","year":"2023","unstructured":"Wang T, et al. Combination of PARP inhibitor and CDK4\/6 inhibitor modulates cGAS\/STING-dependent therapy-induced senescence and provides one-two punch opportunity with anti-PD-L1 therapy in colorectal cancer. Cancer Sci. 2023;114(11):4184\u2013201.","journal-title":"Cancer Sci"},{"issue":"11","key":"15650_CR39","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1038\/s41418-020-0564-6","volume":"27","author":"A Shahbandi","year":"2020","unstructured":"Shahbandi A, et al. BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer. Cell Death Differ. 2020;27(11):3097\u2013116.","journal-title":"Cell Death Differ"},{"issue":"15","key":"15650_CR40","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1158\/1078-0432.CCR-19-1872","volume":"26","author":"JR Whittle","year":"2020","unstructured":"Whittle JR, et al. Dual targeting of CDK4\/6 and BCL2 pathways augments tumor response in Estrogen Receptor-Positive breast cancer. Clin Cancer Res. 2020;26(15):4120\u201334.","journal-title":"Clin Cancer Res"},{"key":"15650_CR41","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jconrel.2020.04.045","volume":"323","author":"I Galiana","year":"2020","unstructured":"Galiana I, et al. Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanosenolytic. J Control Release. 2020;323:624\u201334.","journal-title":"J Control Release"},{"issue":"10","key":"15650_CR42","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/1878-0261.12761","volume":"14","author":"T Saleh","year":"2020","unstructured":"Saleh T, et al. Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X(L) -BAX interaction. Mol Oncol. 2020;14(10):2504\u201319.","journal-title":"Mol Oncol"},{"issue":"1","key":"15650_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01658-w","volume":"9","author":"X Wang","year":"2023","unstructured":"Wang X, et al. Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer. Cell Death Discov. 2023;9(1):355.","journal-title":"Cell Death Discov"},{"key":"15650_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106628","volume":"187","author":"A Estepa-Fern\u00e1ndez","year":"2023","unstructured":"Estepa-Fern\u00e1ndez A, et al. Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer. Pharmacol Res. 2023;187:106628.","journal-title":"Pharmacol Res"},{"issue":"11","key":"15650_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11113066","volume":"11","author":"A Softah","year":"2023","unstructured":"Softah A, et al. The combination of radiation with PARP inhibition enhances senescence and sensitivity to the senolytic, Navitoclax, in triple negative breast tumor cells. Biomedicines. 2023;11(11):3066.","journal-title":"Biomedicines"},{"issue":"5","key":"15650_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s44446-025-00034-2","volume":"33","author":"S Almudimeegh","year":"2025","unstructured":"Almudimeegh S, et al. Talazoparib and radiation enhance the senolytic efficacy of venetoclax in therapy-induced senescent triple-negative breast cancer cells. Saudi Pharm J. 2025;33(5):31.","journal-title":"Saudi Pharm J"},{"issue":"7","key":"15650_CR47","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1158\/0008-5472.CAN-07-5031","volume":"68","author":"CL Hann","year":"2008","unstructured":"Hann CL, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008;68(7):2321\u20138.","journal-title":"Cancer Res"},{"issue":"6","key":"15650_CR48","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/1078-0432.CCR-10-2353","volume":"17","author":"N Tan","year":"2011","unstructured":"Tan N, et al. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res. 2011;17(6):1394\u2013404.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"15650_CR49","doi-asserted-by":"publisher","first-page":"e13142","DOI":"10.1111\/acel.13142","volume":"19","author":"E Gonz\u00e1lez-Gualda","year":"2020","unstructured":"Gonz\u00e1lez-Gualda E, et al. Galacto-conjugation of navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity. Aging Cell. 2020;19(4):e13142.","journal-title":"Aging Cell"},{"issue":"1","key":"15650_CR50","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s43587-024-00747-4","volume":"5","author":"S Magkouta","year":"2025","unstructured":"Magkouta S, et al. Generation of a selective senolytic platform using a micelle-encapsulated Sudan black B conjugated analog. Nat Aging. 2025;5(1):162\u201375.","journal-title":"Nat Aging"},{"issue":"7","key":"15650_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071706","volume":"14","author":"M Yamamoto","year":"2022","unstructured":"Yamamoto M, et al. Gemcitabine cooperates with everolimus to inhibit the growth of and sensitize malignant meningioma cells to apoptosis induced by navitoclax, an inhibitor of anti-apoptotic BCL-2 family proteins. Cancers. 2022;14(7):1706.","journal-title":"Cancers"},{"issue":"1","key":"15650_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29824-1","volume":"13","author":"M Troiani","year":"2022","unstructured":"Troiani M, et al. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer. Nat Commun. 2022;13(1):2177.","journal-title":"Nat Commun"},{"key":"15650_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116385","volume":"226","author":"V Carpenter","year":"2024","unstructured":"Carpenter V, et al. Androgen deprivation-induced senescence confers sensitivity to a senolytic strategy in prostate cancer. Biochem Pharmacol. 2024;226:116385.","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"15650_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03126-0","volume":"11","author":"Q Hu","year":"2020","unstructured":"Hu Q, et al. Metformin as a senostatic drug enhances the anticancer efficacy of CDK4\/6 inhibitor in head and neck squamous cell carcinoma. Cell Death Dis. 2020;11(10):925.","journal-title":"Cell Death Dis"},{"issue":"4","key":"15650_CR55","volume":"7","author":"MM Hoque","year":"2024","unstructured":"Hoque MM, et al. Senolysis of gemcitabine-induced senescent human pancreatic cancer cells. Cancer Rep. 2024;7(4):e2075.","journal-title":"Cancer Rep"},{"issue":"6","key":"15650_CR56","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.hbpd.2024.06.001","volume":"23","author":"D Revskij","year":"2024","unstructured":"Revskij D, et al. Effects of triggers of senescence and senolysis in murine pancreatic cancer cells. Hepatobiliary Pancreat Dis Int. 2024;23(6):628\u201337.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"15650_CR57","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3389\/fonc.2018.00459","volume":"8","author":"K Kovacovicova","year":"2018","unstructured":"Kovacovicova K, et al. Senolytic cocktail Dasatinib+Quercetin (D\u2009+\u2009Q) does not enhance the efficacy of Senescence-Inducing chemotherapy in liver cancer. Front Oncol. 2018;8:459.","journal-title":"Front Oncol"},{"issue":"21","key":"15650_CR58","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1002\/1878-0261.13312","volume":"16","author":"L Bousset","year":"2022","unstructured":"Bousset L, Gil J. Targeting senescence as an anticancer therapy. Mol Oncol. 2022;16(21):3855\u201380.","journal-title":"Mol Oncol"},{"key":"15650_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071593","author":"N Malaquin","year":"2020","unstructured":"Malaquin N, et al. DNA damage- but not enzalutamide-induced senescence in prostate cancer promotes senolytic Bcl-xL inhibitor sensitivity. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9071593.","journal-title":"Cells"},{"issue":"10","key":"15650_CR60","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/jnci\/djab064","volume":"113","author":"PG Prasanna","year":"2021","unstructured":"Prasanna PG, et al. Therapy-Induced senescence: opportunities to improve anticancer therapy. J Natl Cancer Inst. 2021;113(10):1285\u201398.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"15650_CR61","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0014-4827(61)90192-6","volume":"25","author":"L Hayflick","year":"1961","unstructured":"Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25(3):585\u2013621.","journal-title":"Exp Cell Res"},{"issue":"2","key":"15650_CR62","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"Demaria M, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017;7(2):165\u201376.","journal-title":"Cancer Discov"},{"key":"15650_CR63","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","volume":"75","author":"J Campisi","year":"2013","unstructured":"Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685\u2013705.","journal-title":"Annu Rev Physiol"},{"issue":"6","key":"15650_CR64","first-page":"1876","volume":"62","author":"RH te Poele","year":"2002","unstructured":"te Poele RH, et al. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002;62(6):1876\u201383.","journal-title":"Cancer Res"},{"issue":"38","key":"15650_CR65","doi-asserted-by":"publisher","first-page":"35509","DOI":"10.1074\/jbc.M205477200","volume":"277","author":"LW Elmore","year":"2002","unstructured":"Elmore LW, et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem. 2002;277(38):35509\u201315.","journal-title":"J Biol Chem"},{"issue":"22","key":"15650_CR66","first-page":"5019","volume":"58","author":"X Wang","year":"1998","unstructured":"Wang X, et al. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res. 1998;58(22):5019\u201322.","journal-title":"Cancer Res"},{"issue":"4","key":"15650_CR67","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/acel.12344","volume":"14","author":"Y Zhu","year":"2015","unstructured":"Zhu Y, et al. The achilles\u2019 heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644\u201358.","journal-title":"Aging Cell"},{"issue":"1","key":"15650_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11190","volume":"7","author":"R Yosef","year":"2016","unstructured":"Yosef R, et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun. 2016;7(1):11190.","journal-title":"Nat Commun"},{"key":"15650_CR69","doi-asserted-by":"crossref","unstructured":"Hamburger ECB et al. Targeting breast cancer senescence in 3D models of bone metastasis. bioRxiv, 2025: p. 2025.06.26.661856.","DOI":"10.1101\/2025.06.26.661856"},{"key":"15650_CR70","doi-asserted-by":"publisher","first-page":"e54693","DOI":"10.7554\/eLife.54693","volume":"9","author":"H Cherif","year":"2020","unstructured":"Cherif H, et al. Senotherapeutic drugs for human intervertebral disc degeneration and low back pain. eLife. 2020;9:e54693.","journal-title":"eLife"},{"issue":"16","key":"15650_CR71","doi-asserted-by":"publisher","first-page":"e36483","DOI":"10.1016\/j.heliyon.2024.e36483","volume":"10","author":"EF Greenberg","year":"2024","unstructured":"Greenberg EF, et al. Navitoclax safety, tolerability, and effect on biomarkers of senescence and neurodegeneration in aged nonhuman primates. Heliyon. 2024;10(16):e36483.","journal-title":"Heliyon"},{"key":"15650_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176298","volume":"964","author":"C Li","year":"2024","unstructured":"Li C, et al. Fisetin suppresses ferroptosis through Nrf2 and attenuates intervertebral disc degeneration in rats. Eur J Pharmacol. 2024;964:176298.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"15650_CR73","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41591-018-0092-9","volume":"24","author":"M Xu","year":"2018","unstructured":"Xu M, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246\u201356.","journal-title":"Nat Med"},{"key":"15650_CR74","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","volume":"47","author":"LJ Hickson","year":"2019","unstructured":"Hickson LJ, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446\u201356.","journal-title":"EBioMedicine"},{"key":"15650_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104481","volume":"90","author":"A Nambiar","year":"2023","unstructured":"Nambiar A, et al. Senolytics dasatinib and Quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. EBioMedicine. 2023;90:104481.","journal-title":"EBioMedicine"},{"issue":"1","key":"15650_CR76","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ygyno.2022.01.021","volume":"165","author":"F Joly","year":"2022","unstructured":"Joly F, et al. A phase II study of navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: the MONAVI - GINECO study. Gynecol Oncol. 2022;165(1):30\u20139.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"15650_CR77","doi-asserted-by":"publisher","first-page":"100056","DOI":"10.1016\/j.bneo.2024.100056","volume":"2","author":"N Pemmaraju","year":"2025","unstructured":"Pemmaraju N, et al. Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response. Blood Neoplasia. 2025;2(1):100056.","journal-title":"Blood Neoplasia"},{"issue":"9","key":"15650_CR78","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1038\/s41591-025-03873-7","volume":"31","author":"N Liu","year":"2025","unstructured":"Liu N, et al. Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results. Nat Med. 2025;31(9):3047\u201361.","journal-title":"Nat Med"},{"issue":"15","key":"15650_CR79","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, et al. Venetoclax combined with Low-Dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol. 2019;37(15):1277\u201384.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15650-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15650-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15650-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:03:31Z","timestamp":1774620211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15650-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15650"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15650-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}